Ensysce Biosciences Inc.
1430 O'Brien Drive
Suite G
Menlo Park
California
94025
United States
97 articles about Ensysce Biosciences Inc.
-
Ensysce Biosciences Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results~ Corporate Update Call to be Held Wednesday, April 6, 2022 ~
3/31/2022
Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance with a current focus on reducing abuse and overdose, today reported financial results for the fourth quarter and full year 2021.
-
Ensysce Biosciences Announces Participation in the 34th Annual Roth Conference
2/23/2022
Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), today announced management’s participation in the 34th Annual Roth Conference being held March 13-15, 2022 at the Ritz Carlton, Laguna Niguel in Dana Point, California.
-
Ensysce Biosciences Appoints Industry Veteran Lee Rauch to Board of Directors
2/8/2022
Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), today announced that Lee Rauch has been appointed to the Company’s board of directors.
-
Ensysce Biosciences Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communication Program
1/31/2022
Ensysce Biosciences, Inc. announced today the Company has engaged international investor relations specialists MZ Group (“MZ”) to lead a comprehensive strategic investor relations and financial communications program.
-
Ensysce Biosciences Announces Results of Special Meeting of Stockholders
1/27/2022
Ensysce Biosciences, Inc. today announced the results of the special meeting of stockholders held January 26, 2022.
-
Ensysce Biosciences Reminds Stockholders to Vote at Upcoming Special Meeting
1/19/2022
Ensysce Biosciences, Inc., a clinical-stage biotech company with novel technology platforms that may provide new hope for those in severe pain, reminded stockholders to vote at the upcoming special meeting of stockholders to be held on January 26, 2022 at 12:00 pm ET.
-
Ensysce Biosciences Announces First Cohort Dosing in Bioequivalence (BE) Study of Novel “TAAP” OpioidBE Study of PF614 Provides Critical Step toward FDA Approval
1/10/2022
Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with two novel technology platforms designed to provide relief for those suffering with severe pain while protecting against abuse and overdose, announced today the initiation and first dosing in the Bioequivalence (BE) trial of the novel Trypsin Activated Abuse Protected (TAAP) Opioid, PF614.
-
Ensysce Biosciences Announces Participation in the H.C. Wainwright BIOCONNECT Conference
1/5/2022
Ensysce Biosciences, Inc., a clinical-stage biotech company with novel technology platforms that may provide new hope for those in severe pain, announced management’s participation in the H.C. Wainwright BIOCONNECT Conference being held virtually January 10-13, 2022.
-
Ensysce Biosciences Achieves Successful Completion of Part A of Multiple-Ascending Dose (MAD)/Bioequivalents (BE) Trial for its Next Generation Opioid, PF614
1/4/2022
Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), today announced that it has successfully completed Part A of the previously announced clinical study PF614-102, “A Phase 1b, Randomized, 2-Part Single-Center Study to Evaluate the Pharmacokinetics (PK) and Safety of Multiple-Ascending Oral Doses (MAD) of PF614 and the Food Effect and Bioavailability/Bioequivalence (BE) of Single Oral Doses of PF614 Relative to OxyContin in Healthy Adult Subjects.”
-
Ensysce Biosciences Announces First Patients Enrolled in Phase 1 Study of PF614-MPAR™, its unique technology platform to provide opioid overdose protection
12/15/2021
Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), today announced that the first patients have been enrolled in the Phase 1 study of PF614-MPARTM, the first product utilizing the Company’s MPARTM platform designed to reduce opioid overdose.
-
Ensysce Biosciences Announces Clinical Trial Progress of its New Class of Opioids
11/30/2021
Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), today announced the completion of a positive safety review and enrollment of the last cohort of subjects at the highest dose level in the Company’s second study of its Trypsin Activated Abuse Protected (TAAP) Opioid, PF614.
-
Ensysce Biosciences Reports Third Quarter 2021 Financial Results and Recent Corporate Updates
11/15/2021
Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, today reported financial results for the third quarter of 2021 and recent corporate updates.
-
Ensysce Biosciences Announces Completion of $15 Million Convertible Note Financing
11/8/2021
Ensysce Biosciences, Inc. announced today that it has completed its previously announced private placement under a securities purchase agreement with institutional investors (“Investors”) for senior secured convertible notes
-
Ensysce Biosciences Grows its Management Team with Appointment of Dr. Linda Pestano as Chief Development Officer
10/26/2021
Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, has appointed Linda Pestano, PhD, Chief Development Officer effective October 15, 2021.
-
Ensysce Biosciences Announces $15 Million Convertible Note Financing
9/27/2021
Ensysce Biosciences, Inc. announced today that it has entered into a securities purchase agreement with institutional investors (“Investors”) in the form of senior secured convertible notes
-
Ensysce Biosciences Announces Treatment of First Cohort for Subjects in Clinical Study of its Next Generation Opioid, PF614
9/8/2021
Ensysce Biosciences, Inc. announced that it has enrolled the first cohort of subjects in a clinical study PF614-102 entitled “A Phase 1b, Randomized, 2-Part Single-Center Study to Evaluate the Pharmacokinetics and Safety of Multiple-Ascending Oral Doses of PF614 and the Food Effect and Bioavailability/Bioequivalence of Single Oral Doses of PF614 Relative to OxyContin in Healthy Adult Subjects.”
-
Ensysce Biosciences Sets September 2021 Conference Schedule
8/31/2021
Ensysce Biosciences, Inc. is scheduled to participate at the following industry and financial conferences during September 2021: 10th Annual Gateway Conference Date and Time : Held virtually on September 8-9, 2021
-
Ensysce Biosciences to Host Satellite Symposium with Dr. Jeffrey Gudin at PAINWeek 2021 on September 9, 2021
8/19/2021
Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, today announced it will sponsor a satellite symposium at PAINWeek 2021 on Thursday, September 9 from 3:40 p.m. to 4:30 p.m. Eastern Time (12:40 p.m. to 1:30 p.m. Pacific Time) in Castellana 1 Ballroom, The Cosmopolitan of Las Vegas
-
Ensysce Biosciences Reports Second Quarter 2021 Financial Results and Recent Corporate Updates
8/16/2021
Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, today reported financial results for the second quarter of 2021 and recent corporate updates.
-
Ensysce Biosciences Announces Notice of Allowance from the U.S. Patent and Trademark Office for Patent Entitled “Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof”
8/5/2021
Ensysce Biosciences, Inc., a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, announced that the United States Patent and Trademark Office has granted Notice of Allowance for a patent entitled Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof.